Kurma Partners, a private investment firm focused on improving human health, has held the first close of Biofund IV with €140m in capital commitments, over half of the €250m total the firm is targeting at final close in 2025.
Biofund IV will look to make 16 to 20 new investments in total, of which the first three have already been made.
Like its predecessors, Biofund IV will be dedicated to companies developing innovative therapeutics, aiming for a balanced, risk-managed strategy, with investments for company creation as well as in established venture-stage companies. Kurma remains thematically agnostic and will continue to opportunistically pursue the forefront of innovation, to identify and create future industry trends.
Biofund IV three investments to date are autoimmune company SciRhom, natural immunity inspired Memo Therapeutics and cancer immunotherapeutics company Avidicure.
